Abeona Therapeutics (NASDAQ:ABEO)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a note issued to investors on Thursday. They presently have a $30.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price objective would suggest a potential upside of 96.72% from the stock’s previous close.
A number of other equities research analysts have also issued reports on the company. Royal Bank of Canada reaffirmed a “buy” rating and issued a $26.00 target price on shares of Abeona Therapeutics in a research note on Wednesday, January 24th. BidaskClub lowered Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, January 23rd. ValuEngine lowered Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Zacks Investment Research lowered Abeona Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, November 23rd. Finally, Jefferies Group reaffirmed a “buy” rating and issued a $28.00 target price on shares of Abeona Therapeutics in a research note on Wednesday, November 22nd. Two analysts have rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $26.40.
Shares of Abeona Therapeutics (ABEO) opened at $15.25 on Thursday. The company has a market capitalization of $715.66, a P/E ratio of -23.11 and a beta of 2.21. Abeona Therapeutics has a 52 week low of $4.50 and a 52 week high of $22.75.
A number of institutional investors and hedge funds have recently modified their holdings of ABEO. State Street Corp acquired a new position in Abeona Therapeutics in the 2nd quarter valued at $1,900,000. Point72 Asset Management L.P. acquired a new position in Abeona Therapeutics in the 3rd quarter valued at $3,527,000. Northern Trust Corp raised its holdings in Abeona Therapeutics by 406.3% in the 2nd quarter. Northern Trust Corp now owns 257,668 shares of the biopharmaceutical company’s stock valued at $1,649,000 after acquiring an additional 206,775 shares during the last quarter. EAM Investors LLC acquired a new position in Abeona Therapeutics in the 3rd quarter valued at $2,509,000. Finally, Vanguard Group Inc. raised its holdings in Abeona Therapeutics by 11.2% in the 2nd quarter. Vanguard Group Inc. now owns 1,081,670 shares of the biopharmaceutical company’s stock valued at $6,922,000 after acquiring an additional 108,730 shares during the last quarter. Institutional investors own 41.97% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Abeona Therapeutics (ABEO) Earns “Buy” Rating from HC Wainwright” was reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.com-unik.info/2018/02/01/abeona-therapeutics-abeo-earns-buy-rating-from-hc-wainwright.html.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.